Effects of Baduanjin Exercise on Heart Failure Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with stable heart failure by a physician according to the New York Heart Association (NYHA) class I and II
- Aged 20 years or older
- Able to communicate and speak Chinese
- Have video devices available to use at home
Exclusion Criteria:
- Impaired mobility, defined as a limitation in independent, purposeful physical movement of the body or of one or more extremities
- Unstable angina or myocardial infarction, unstable serious arrhythmia, unstable structural valvular disease, open-heart surgery, or chronic obstructive pulmonary disease (COPD)
- Diagnosis of major depression and cognitive disorders
- Unstable vital signs (defined as blood pressure > 180/110 mmHg or < 90/60 mmHg and resting heart rate > 100 beats/min).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control group
Patients in this group maintain their daily life activities, and there is no intervention given.
|
|
|
Experimental: Baduanjin exercise group
The Baduanjin exercise group received a 12-week Baduanjin exercise programme.
|
Patients in the intervention group underwent a 12-week Baduanjin exercise programme consisting of 12 weeks of Baduanjin exercise, a 35-min Baduanjin exercise demonstration video, a picture-based educational brochure, and a performance record form.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in the modified Piper Fatigue Scale scores
Time Frame: baseline, 4 week, 8 week, 12 week
|
Changes from baseline modified Piper Fatigue scale at 4 weeks, 8 weeks, 12 weeks.The shortened modified Piper Fatigue scale is composed of 15 items that measure two domains of fatigue: severity and temporality.
Each item is scored from 0 to 3, with a total possible score of 0-45.
Higher scores indicate greater fatigue.
|
baseline, 4 week, 8 week, 12 week
|
|
Changes in the Minnesota Living with Heart Failure Questionnaire scores
Time Frame: baseline, 4 week, 8 week, 12 week
|
Changes from baseline Minnesota Living with Heart Failure Questionnaire at 4 weeks, 8 weeks, 12 weeks.The Minnesota Living with Heart Failure Questionnaire is composed of 21 items.
Each item score ranges from 0 to 5. The total possible score ranges from 0 to 105, with higher scores indicating a lower quality of life.
|
baseline, 4 week, 8 week, 12 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in the Pittsburgh Sleep Quality Index scores
Time Frame: baseline, 4 week, 8 week, 12 week
|
Changes from baseline Pittsburgh Sleep Quality Index at 4 weeks, 8 weeks, 12 weeks.The Pittsburgh Sleep Quality Index is composed of 21 items, 7 dimensions.
Each dimension is scored from 0 to 3, with a total possible score of 0-21.
Higher scores indicate poor sleep.
|
baseline, 4 week, 8 week, 12 week
|
|
Changes in the Hospital Anxiety and Depression Scale scores
Time Frame: baseline, 4 week, 8 week, 12 week
|
Changes from baseline Hospital Anxiety and Depression Scale at 4 weeks, 8 weeks, 12 weeks.The Hospital Anxiety and Depression Scale is composed of 14 items, 2 subscales.
Each item is scored from 0 to 3, with a total possible score of 0-21 for each subscale.
Higher scores indicate higher anxiety and depression
|
baseline, 4 week, 8 week, 12 week
|
|
Changes in heart rate variability
Time Frame: baseline, 4 week, 8 week, 12 week
|
Changes from baseline heart rate variability at 4 weeks, 8 weeks, 12 weeks.The heart rate variability was measured using the "Heart Rate Master ANSWatch® Wrist Physiological Monitor TS-0411Deluxe Advanced" (made in Taiwan)
|
baseline, 4 week, 8 week, 12 week
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 13-S-013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.